Tolcapone and Hepatotoxic Effects

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

Tolcapone and entacapone are catechol-O-methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson's disease. While both drugs have been shown to cause mitochondrial dysfunction and inhibition of the bile salt export protein (BSEP), liver injury has only been associated with the use of tolcapone. Here we used a multiscale, mechanistic model (DILIsym(®)) to simulat...

Hepatotoxic Effects of Lipid-altering Agents

Dyslipidemia is a major risk factor for coronary heart disease (CHD), and current guidelines support low-density lipoprotein cholesterol (LDL-C) as a primary target of therapy.[1] Previous studies suggest that increasing high-density lipoprotein cholesterol (HDL-C) and reducing triglycerides and small LDL particles may also have a positive impact in prevention.[2] These factors are considered s...

TASMAR (tolcapone) TABLETS

Hepatotoxic effects of vincristine: an experimental study on albino rats.

Vincristine (VCR) is an established drug of choice in treatment of some myelomas, lymphomas and leukemias. Hepatotoxicity is a lesser studied side effect of the drug. Samples of blood and other tissues were collected for morphological, biochemical and histopathological evaluation 2 and 24 hours after single intravenous administration of 1.0 mg/kg of VCR to male Albino Wistar rats. VCR produced ...

Utility of tolcapone in fluctuating Parkinson’s disease

Fluctuating Parkinson's disease (PD) represents a clinical management challenge. The primary utility of levodopa in patients with PD is moderated by the "wearing off" phenomena seen with long-term use. COMT inhibitors slow down the rapid metabolism of levodopa, resulting in a more-sustained response to dopaminergic therapy. Tolcapone is a selective, reversible catechol-O-methyltransferase (COMT...